Fig. 2From: Influence of Mitroflow bioprosthesis structural valve deterioration on cardiac morbiditySVD-related complications. Percentage of hospital admissions with heart failure and endocarditis within the three different groups. Group 1: Cardiovascular death due to SVD; Group 2: Cardiovascular death with no SVD; Group 3: Non-cardiovascular death without SVDBack to article page